Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt
This project was supported by contracts between the National Academy of Sciences and the Alzheimer's Association; AstraZeneca Pharmaceuticals, Inc.; CeNeRx Biopharma; the Department of Health and Human Services' National Institutes of Health (NIH, Contract No. N01-OD-4-213) through the National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Eye Institute, NIH Blueprint for Neuroscience Research, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke; Eli Lilly and Company; Foundation for the National Institutes of Health; GE Healthcare, Inc.; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck Research Laboratories; The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. OIA-0753701); Pfizer Inc.; and the Society for Neuroscience.
IOM (Institute of Medicine). 2011. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: A Workshop Summary. Washington, DC: The National Academies Press.
The views presented in this publication are those of the editors and attributing authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project.
NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.